VIGL Vigil Neuro: Forward Price-to-Revenue Multiple
Vigil Neuroscience is optimizing biomaterial supplies and developing neuroimmunological alliances to create protective brain therapies. The forward P/S metric visualizes the effectiveness of this strategy, where indicates the current valuation level. High R&D expenditures and patent protection for microglial drugs create a significant barrier for competitors, ensuring the asset's long-term sustainability.
Analytical breakdowns for Vigil Neuroscience
- current price and projected stock value:
- company stock capitalization data:
- business book valuation details:
- issuer credit burden and liquidity indicators:
Debt to Equity Vigil Neuroscience|VIGL - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Capital Vigil Neuroscience, Inc.|VIGL - Company Total Debt|Debts to Book Capitalization Vigil Neuroscience, Inc.|VIGL - Long-Term Debt Volume|Company Short-Term Debts Vigil Neuroscience|Quick Liquidity vigilneuro.com
- business earnings and investment ratios data:
VIGL - Company Profit|Projected Future Earnings Vigil Neuroscience|VIGL - Price to Earnings Ratio|Forward P/E Multiple Vigil Neuroscience, Inc.|VIGL - Price to Earnings Adjusted for Growth Rate|Enterprise Value to EBITDA Ratio Vigil Neuroscience, Inc.|VIGL - Profit before payment of interest, taxes and amortization|Net earnings per share (EPS TTM) Vigil Neuroscience|VIGL - Net earnings per share for the last four quarters|Quarterly EPS earnings growth vigilneuro.com|VIGL - Net earnings per share change in current year|Net earnings per share growth forecast for next year Vigil Neuroscience
- company sales and revenue statistics:
Analysis of all company metrics:Vigil Neuro VIGL
This indicator compares the current market value of Vigil Neuroscience (VIGL) with projected sales volumes, allowing for an assessment of the premium paid for future cash flows. By analyzing the forward price-to-sales ratio, an investor can see how the resilience of drug substance supply chains reduces operational risks, which directly impacts the company's fundamental value and its investment attractiveness on the chart.
Analysis of competing companies
Forward P/S Multiple BIIB (Biogen)|Neurocrine (NBIX) - Market Cap to Future Revenue Ratio|RGC: Forward Price-to-Revenue Multiple|AXSM - Forward P/S Multiple|ACADIA Pharmaceuticals (ACAD) - Price-to-Projected Revenue Ratio|xenon-pharma.com - Forward Price to Sales|Price-to-Projected Revenue Ratio Viking Therapeutics, Inc.|Market Cap to Future Revenue Ratio Supernus Pharmaceuticals, Inc. SUPN|Price-to-Projected Revenue Ratio Catalyst Pharmaceuticals Inc (CPRX)|Market Cap to Expected Sales Ratio Denali Corp|Forward P/S Multiple HRMY (Harmony Biosciences)|BHVN - Forward Price-to-Revenue Multiple|Amylyx Pharmaceuticals, Inc. - Forward P/S Multiple|Market Cap to Expected Sales Ratio Trevi Therapeutics Inc TRVI|PRAX: Forward P/S Multiple|Market Cap to Future Revenue Ratio Anavex Life Sciences Corp (AVXL)|Price-to-Projected Revenue Ratio CeriBell, Inc.|Market Cap to Projected Revenue PRTA (Prothena Corporation)|Forward P/S Multiple ALEC|Forward Price-to-Revenue Multiple Annexon Biosciences ANNX|Forward P/S Multiple OMER (Omeros)|Neurogene Therapeutics (NGNE) - Market Cap to Future Revenue Ratio|ACIU: Forward Price-to-Revenue Multiple|VYGR: Price-to-Projected Revenue Ratio|NMRA: Forward P/S Multiple|SCLX - Market Cap to Expected Sales Ratio|TVGN (Tevogen Bio Holdings, Inc.) - Forward P/S Multiple|ACOG - Projected Price to Revenue|Price-to-Projected Revenue Ratio Cognition Therapeutics (CGTX)|Price-to-Projected Revenue Ratio IKT (inhibikase.com)|Price-to-Projected Revenue Ratio Cassava Sciences SAVA|ASRT: Market Cap to Projected Revenue|Coya - Forward P/S Multiple|Market Cap to Future Revenue Ratio Vistagen Therapeutics|OVID (ovidrx.com) - Forward Price-to-Revenue Multiple|acumenpharm.com (ABOS) - Forward P/S Multiple|Price-to-Projected Revenue Ratio CervoMed|ATHE: Forward Price to Sales|Price-to-Projected Revenue Ratio Clene Inc. (CLNN)|PEPG - Market Cap to Future Revenue Ratio|Jupiter Neurosciences Inc - Forward Price-to-Revenue Multiple|relmada.com - Price-to-Projected Revenue Ratio|Annovis Bio - Forward P/S Multiple|Market Cap to Expected Sales Ratio Grace Therapeutics, Inc. GRCE|AIFF: Forward P/S Multiple|Projected Price to Revenue Klotho Neurosciences KLTO|NRSN (NeuroSense Therapeutics Ltd) - Forward P/S Multiple|revivapharma.com (RVPH) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio MetaVia Inc (MTVA)|Price-to-Projected Revenue Ratio NRXS (NeurAxis Inc.)|Helius Medical Technologies - Forward Price-to-Revenue Multiple|Forward Price to Sales PASG|NEUP - Price-to-Projected Revenue Ratio|NERV (minervaneurosciences.com) - Market Cap to Projected Revenue|ATHA: Forward P/S Multiple|Market Cap to Future Revenue Ratio Addex Therapeutics Ltd. (ADXN)|Forward Price-to-Revenue Multiple ALZN|Forward P/S Multiple Cyclerion|Price-to-Projected Revenue Ratio Protagenic Therapeutics (PTIX)|KTTA (pasitheaclinics.com) - Forward Price to Sales|Price-to-Projected Revenue Ratio Cortigent CRGT|Avenue Therapeutics Inc. (ATXI) - Market Cap to Future Revenue Ratio|BCLI - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio Cara Therapeutics Inc CARA|CHRO: Forward P/S Multiple|Forward Price-to-Revenue Multiple Eliem Therapeutics Inc.|ITCI (Intra-Cellular Therapies Inc.) - Forward P/S Multiple|Longboard Pharmaceuticals Inc (LBPH) - Market Cap to Expected Sales Ratio|Forward P/S Multiple MRNS|NKGN - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio NeuroBo Pharmaceuticals NRBO|SAGE: Market Cap to Projected Revenue|Synaptogenix - Forward P/S Multiple|Trevena Inc. (TRVN) - Forward Price-to-Revenue Multiple|WENA: Forward P/S Multiple|Market Cap to Future Revenue Ratio Cerevel Corp (CERE)
